Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Esperion Therapeutics, Inc. reported revenue of $403M, up 21.3% year over year. Operating margin was 15.0% and net margin -5.6%, on a free-cash-flow margin of -3.2% with capital expenditure at 0.0% of revenue. Every figure is computed directly from ESPR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $403M | 15.0% | -5.6% |
| FY2024 | $332M | 16.4% | -15.6% |
| FY2023 | $116M | -133.7% | -179.9% |
| FY2022 | $75M | -237.8% | -309.6% |
| FY2021 | $78M | -289.0% | -343.0% |
How does ESPR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.